Michael Blute Sr., MD, has worked continuously to increase awareness of genitourinary cancer as he helps Mass General continue its leadership role in tackling urology issues.
As chief of the Mass General Department of Urology, and the Walter S. Kerr, Jr. Professor of Urology at Harvard Medical School, Dr. Blute is deeply focused on all issues pertaining to prostate, bladder, kidney and testis cancer. As the second leading cause of cancer death in men, prostate cancer demands the kind of thorough and innovative thinking which are hallmarks of Dr. Blute’s clinical and academic career. Bladder and kidney cancer are also on the top ten list of cancers that affect men and women in the U.S.
At Mass General, Dr. Blute leads a team of dedicated urologists who treat kidney, bladder and prostate cancer. This team focuses on teaching the next generation of physicians, as well as the analyzing of outcomes research as a way to determine if a protocol is working. In addition, Dr. Blute’s team is analyzing utilization of robotics as a minimally invasive treatment option for patients with genitourinary cancer. Recently, the Urology Department opened a new space dedicated to patient care, centered on an approach that puts the patient’s needs first.
Dr. Blute serves as a reviewer on 13 editorial boards. He also served on the AUA Renal Mass Guideline Panel and the American Joint Committee on Cancer. He is the recipient of the 2010 AUA Career Contribution Award and the Andrew C. Novick Lecturer and Contribution Award from the Kidney Cancer Association in 2012. His bibliography includes 387 peer-reviewed publications, one book and 26 book chapters.
